

# **Q&M Dental Group** (QNM SP)

# Searching for the bottom

### 1H23 profit below street; lowering EPS and TP

We just attended QNM's post-results briefing for an update. As a recap, the group's 1H23 net profit of SGD5.3m (-46% YoY) missed our and street expectations. While its core healthcare business remains resilient, this was offset by weakening MYR for its Malaysian operations, higher finance costs and less contribution from medical laboratory. To conserve cash, QNM reduced its interim DPS to 0.16 cent (1H23: 0.4 cent). We cut our FY23-25E EPS by 25-34% on slower dental topline growth, exacerbated by negative operating leverage. Retain HOLD with a lower TP of SGD0.31, based on 24x FY24E P/E (5-year average). We prefer Raffles Medical (RFMD SP, BUY, TP: SGD1.65) within the Singapore's healthcare sector.

### Aims to improve efficiency to cut costs & wastage

1H23 revenue from the core healthcare business was down 0.5% YoY to SGD83.3m, mainly due to steady performance from Singapore dental clinics but offset by weaker sales from its medical clinics in Malaysia, as well as unfavourable FX impact of a strong SGD against MYR. Meanwhile, medical laboratory turnover fell 46.6% to SGD3.8m due to less PCR testing post re-opening. To mitigate rising staff/rental costs, the group plans to use central purchasing to cut wastage, and ensure more just-in-time ordering so that it can also reduce storage cost to improve efficiency.

### Investing in data-centric AI treatments

To achieve higher productivity and organic growth, QNM aims to recruit more dentists, especially for its top-performing clinics. It is also trying to develop and optimise its digital AI guided clinical decision support system to provide more effective and suitable treatment plans for patients. While this may cater to the growing demand for high-value specialist dental healthcare services, we think gestation losses in this venture could continue to weigh on its earnings in the near term.

### Developing new tests for other medical purposes

Post-pandemic, QNM's medical laboratory business, Acumen Diagnostic, will seek to develop a new range of tests and solutions to maximise its intellectual property and research capabilities for various medical purposes. These include tests for sepsis, identification of bacteria pathogens and their associated antimicrobial resistance in hospitalised pneumonia. To be conservative, we have yet to assume any potential income stream from this pipeline given the lack of clear visibility on commercialisation and/or timeline.

FYE Dec (SGD m)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue	206	181	175	178	180
EBITDA	64	36	37	39	41
Core net profit	26	16	11	12	14
Core EPS (cts)	2.8	1.7	1.1	1.3	1.5
Core EPS growth (%)	12.1	(38.9)	(34.2)	14.5	12.9
Net DPS (cts)	4.0	1.0	0.5	0.8	1.0
Core P/E (x)	21.6	18.4	25.7	22.5	19.9
P/BV (x)	5.8	3.1	3.0	3.3	3.8
Net dividend yield (%)	6.6	3.2	1.7	2.6	3.4
ROAE (%)	27.8	11.6	11.4	14.1	17.8
ROAA (%)	9.6	6.0	4.0	4.8	5.5
EV/EBITDA (x)	9.5	9.6	8.3	8.0	7.7
Net gearing (%) (incl perps)	28.8	36.9	38.8	44.2	50.9
Consensus net profit	-	-	na	na	na
MIBG vs. Consensus (%)	-	-	na	na	na

Eric Ong ericong@maybank.com (65) 6231 5849

# HOLD

Share Price SGD 0.29
12m Price Target SGD 0.31 (+7%)
Previous Price Target SGD 0.37

#### **Company Description**

Q&M Dental is one of the leading integrated dental healthcare groups in Asia, which owns the largest network of private dental outlets in Singapore


#### **Statistics**

52w high/low (SGD)	0.41/0.28
3m avg turnover (USDm)	0.1
Free float (%)	32.2
Issued shares (m)	966
Market capitalisation	SGD280.1M
	USD206M

#### Major shareholders:

Quan Min Holdings Pte Ltd.	52.0%
Heritas Capital Management Pte Ltd.	6.6%
Q & M Dental Group (Singapore) Ltd.	2.0%

#### **Price Performance**



Q&M Dental - (LHS, SGD) ——Q&M Dental / Straits Times Index - (RHS, %)

	-1M	-3M	-12M
Absolute (%)	(6)	(5)	(26)
Relative to index (%)	(3)	(3)	(23)

Source: FactSet






## Value Proposition

- Fills the gap between cheap-but-slow public dental services and premium services.
- Group model enables dentists to concentrate on core duties and leverage the firm's strong branding to attract patients.
- Healthy balance sheet with low gearing provides ample headroom for more organic expansion and accretive M&A.

### No. of dentists per 10,000 people



Source: Company, Maybank IBG Research

## **Price Drivers**

#### Historical share price trend




Source: Company, Maybank IBG Research

- 1. Proposed disposal of 36% stake in Aidite for SGD49m, giving rise to an estimated one-off gain of SGD19m. Net proceeds used for working capital and business expansion purposes.
- Appoints Azion Healthcare as the exclusive distributor for cu-Corona® 3.0 in Mexico.
- Its 51%-owned subsidiary, Acumen was granted a healthcare institution licence from MOH to conduct SARS-CoV-2 PCR testing services for COVID-19.
- In Oct 22, the group won a tender worth at least SGD3.6m from MOH for the operation of a Joint Testing & Vaccination Centre.

### **Financial Metrics**

- We expect overall revenue to decline due to lower PCR testing turnover, but partly offset by contribution from new outlets.
- However, higher capex is expected as the Group progressively opens more dental clinics in Singapore and Malaysia over the next few years.
- Free cash flow is likely to stay positive given its robust cash generating business model.

# EPS, FCF per share and DPS



### **Swing Factors**

### Upside

- Better-than-expected sale of Covid-19 test kits and laboratory testing.
- Ability to add more dental clinics at strategic locations to entrench its dominant market position.
- Potential accretive M&A to accelerate growth given the group's conservative balance sheet.

#### Downside

- Unable to attract new dentists or longer-than-expected gestation loss at new outlets.
- Lower patient volumes due to imposition of stricter measures amid another Covid-19 resurgence.
- Market share loss in its key markets due to keen competitive pressures from other players.

ericong@maybank.com

**Q&M Dental Group** 





ericong@maybank.com

Risk Rating & Score <sup>1</sup>	na
Score Momentum <sup>2</sup>	na
Last Updated	na
Controversy Score <sup>3</sup>	na

### **Business Model & Industry Issues**

- As a dental services provider, its first priority was the safety of all patients and employees amid the current COVID-19 pandemic and it had implemented tighter access and strict infection control protocols.
- In managing its supply chain, the Group ensures that its suppliers are continually assessed by management in accordance with the guiding principles established in its procurement policies.
- On the clinical front, it is working towards gradually obtaining "Eco-Shop" certifications at its clinics over the next few years. This is aimed at guiding and encouraging retailers to fit out their shops in an environmentally-sustainable manner, as well as to adopt eco-friendly habits and implement green practices in their daily operations.

### Material E issues

- Q&M handles different types of clinical waste on a daily basis and it is important that its waste management process is conducted under a safe and sustainable manner.
- Licensed waste disposal vendors are engaged to collect and dispose sharps and biohazardous waste to ensure adherence to requirements stated in the Private Hospital and Medical Clinics Act by the Ministry of Health.
- The Group has yet to implement tracking mechanism to measure the quantity of waste disposed. However, the vendors it engaged have a proper system in place to collate data on the amount of waste collected to analyse.
- It will ensure all the defective ionising radiation irradiating apparatus such as x-ray machines are properly returned to the equipment vendor/distributor for proper disposal.
- There were no reported non-compliances with regulations relating to disposal of hazardous and non-hazardous waste.

### Material S issues

- As at 31 Dec 2021, the group has a total of 713 employees under its Singapore and Malaysia operations. Of which, 77 are temporary employees and they are treated in accordance with salary practices in the region it operates in as part of the fair working environment practice.
- To ensure sustainability of its pool of dentists, the Group has launched its first private dentistry institution in Singapore, Q&M College of Dentistry which offers postgraduate diploma studies in clinical dentistry and Q&M Dental Group Scholarship Scheme in Oct '19.
- All dentists must meet the mandatory requirements under the Dental Registration Act and the Medical Registration Act respectively. They are also required to fulfil certain number of hours of Continuing Professional Education in order to proceed with their practicing certificates renewal.
- In FY21, there were 3 minor and non-fatal workplace accidents where clinic assistants suffered cuts and/or pricks by needles.

### Key G metrics and issues

- Board consists six directors, of whom two are executive directors, one is a non-executive, non-independent chairman, and three are independent (50%). There is one female director.
- The nominating, audit and remuneration committees are chaired by independent directors.
- Founder and CEO Dr. Ng Chin Siau's deemed stake in company is approximately 54.46%.
- Two independent directors have served more than nine years from date of appointments. This will be taken into consideration when evaluating its board renewal.
- Diversified background of independent directors from legal and accounting with strong industry knowledge.
- Key management/ directors' compensation accounted for c.2%/1% of total employee compensation in 2021.
- Auditor is RSM Chio Lim LLP, which were appointed in 2016.
- It has a zero tolerance approach towards corrupt and dishonest practices or acts of bribery to obtain an unfair advantage and its employees are expected to report any concerns or unethical behaviour.
- All complaints or information would be forwarded to the Chairman of AC or CFO. There was no reported incident pertaining to whistle blowing during FY21.
- In Sep '20, the Group had discovered a case relating to the misappropriation of company's funds which involved two employees from its clinics in Johor. A police report was immediately lodged following the discovery of the incident and the investigation is still ongoing.
- In Jan '21, Q&M reached a full settlement for RM3.5m against Madam Chong Lee Lee and her husband, Dr Hong An Liang on claim that the duo transferred company funds into their personal accounts. Thy also had set up a competing outfit behind Q&M Johor clinics, using its resources without permission.

<u>Risk Rating & Score</u> - derived by Sustainalytics and assesses the company's exposure to unmanaged ESG risks. Scores range between 0 - 50 in order of increasing severity with low/high scores & ratings representing negligible/significant risk to the company's enterprise value, respectively, from ESG-driven financial impacts. <u>\*2Score Momentum</u> - indicates changes to the company's score since the last update - a <u>negative</u> integer indicates a company's improving risk score; a <u>positive</u> integer indicates a deterioration. <u>\*3Controversy Score</u> - reported periodically by Sustainalytics in the event of material ESG-related incident(s), with the impact severity scores of these events ranging from Category 0-5 (0 - no reports; 1 - negligible risks; ...; 5 - poses serious risks & indicative of potential structural deficiencies at the company).



	Quantitative parameters (Score: 30)								
	Particulars	Unit	2020	2021	2022	RFMD SP (2022)			
	Scope 1 GHG emissions	m tCO2e	N/A	N/A	N/A	N/A			
	Scope 2 GHG emissions	m tCO2e	N/A	N/A	N/A	N/A			
	Total	m tCO2e	N/A	N/A	N/A	N/A			
	Scope 3 GHG emissions	m tCO2e	N/A	N/A	N/A	N/A			
	Total	m tCO2e	N/A	N/A	N/A	N/A			
	GHG intensity (Scope 1 and 2)	tCO2e/t	N/A	N/A	N/A	N/A			
Ε	Energy intensity Ratio	KWh/m <sup>2</sup>	190.3	161.1	154.2	N/A			
	Share of renewable energy use in operations	%	N/A	N/A	N/A	N/A			
	Wastewater discharge (chemical O2 demand)	tonnes	N/A	N/A	N/A	N/A			
	Hazardous waste 3R rate	%	N/A	N/A	N/A	0.014			
	Air emissions intensity	ton/kT	N/A	N/A	N/A	N/A			
	NPE (New Plastic Economy) investments	SGD m	N/A	N/A	N/A	N/A			
	Cases of environmental non-compliance	number	0	0	0	0			
	% of women in workforce	%	78%	84%	<b>79</b> %	N/A			
S	% of women in management roles	%	29%	33%	54%	27%			
3	Lost time injury frequency (LTIF) rate	number	0.0	0.0	0.0	0.0			
	Employee volunteerism	hours	N/A	N/A	N/A	7176			
	ED/CEO salary as % of reported net profit	%	3.6%	10.8%	10.4%	2.6%			
G	Board salary as % of reported net profit	%	3.2%	2.6%	6.0%	4.0%			
G	Independent directors on the Board	%	37.5%	37.5%	44.4%	45%			
	Female directors on the Board	%	12.5%	12.5%	11.1%	18%			

#### Qualitative Parameters (Score: 68)

a) Is there an ESG policy in place and is there is a standalone ESG committee or is it part of the risk committee?

Yes. Led by the CEO and COO, the committee oversees the implementation of the group's overall sustainability strategy.

b) Is the senior management salary linked to fulfilling ESG targets?

No

- c) Does the company follow the task force of climate related disclosures (TCFD) framework for ESG reporting?
- e) Does the company have a mechanism to capture Scope 3 emissions which parameters are captured? *No*
- f) What are the 2-3 key carbon mitigation/water/waste management strategies adopted by the company?
- 1) Installation of thimbles in taps; 2) all new clinics were installed with refrigerated areas to store clinical waste prior to disposal; and 3) engaged licensed-waste-disposal suppliers to collect and dispose of sharp and biohazardous waste.
- g) Does carbon offset form part of the net zero/carbon neutrality target of the company?

Yes

Target (Score: 80)							
Particulars	Target	Achieved					
Reduce average water consumption per clinic	N/A	100%					
Reduce electricity consumption per clinic	N/A	100%					
Minimise clinical waste per clinic	N/A	100%					
Maintain zero-reported data privacy incidents	0	100%					
Increase average training hours for staff	3.0	2.9					
Impact	Impact						
NA							
Overall score: 52							
As per our ESG matrix, Q&M Dental (QNM SP) has an overall score of 52.							

ESG score	Weights	Scores	Final Score
Quantitative	50%	30	15
Qualitative	25%	68	17
Target	25%	80	20
Total			52


As per our ESG assessment, Q&M has an established framework, internal policies, and tangible mid/long-term targets but needs to make headway in improving its quantitative "E" metrics YoY. Its overall ESG score is 52, which makes its ESG rating above average in our view (average ESG rating = 50).

Fig 1: Earnings revisions

		FY23E	-	-	FY24E	-	-	FY25E	
(SGD m)	New	Old	Chg (%)	New	Old	Chg (%)	New	Old	Chg (%)
Revenue	175.1	183.2	-4.4%	177.7	186.8	-4.9%	180.4	190.5	-5.3%
EBITDA	37.3	42.7	-12.6%	39.0	44.3	-11 <b>.9</b> %	40.8	45.8	-10 <b>.9</b> %
EBIT	19.5	24.7	-21.0%	21.0	25.8	-18.4%	22.6	26.8	-15.6%
Core net profit	10.7	16.2	-33.9%	12.2	17.3	-29.4%	13.8	18.4	-25.1%
DPS (cts)	0.5	1.0	-50.0%	0.8	1.0	-25.0%	1.0	1.0	0.0%
			Chg (ppt)			Chg (ppt)			Chg (ppt)
EBIT margin	11.1%	13.5%	-2.3%	11.8%	13.8%	-2.0%	12.5%	14.1%	-1.5%
Net margin	6.1%	8.8%	-2.7%	6.9%	9.3%	-2.4%	7.6%	9.7%	-2.0%

Source: Company, Maybank IBG Research

Fig 2: Forward PE valuation band



Source: Factset

FYE 31 Dec	FY21A	FY22A	FY23E	FY24E	FY25E
Key Metrics					
P/E (reported) (x)	17.4	37.6	25.7	22.5	19.9
Core P/E (x)	21.6	18.4	25.7	22.5	19.9
P/BV (x)	5.8 13.3	3.1 7.3	3.0 8.9	3.3 12.7	3.8 23.3
P/NTA (x) Net dividend yield (%)	6.6	7.3 3.2	1.7	2.6	3.4
FCF yield (%)	7.4	3.2 7.7	10.7	10.3	11.3
EV/EBITDA (x)	9.5	9.6	8.3	8.0	7.7
EV/EBIT (x)	12.1	18.3	15.9	14.8	13.9
INCOME STATEMENT (SGD m)					
Revenue	205.6	181.2	175.1	177.7	180.4
EBITDA	63.7	35.8	37.3	39.0	40.8
Depreciation	(13.6)	(17.1)	(17.8)	(18.0)	(18.2)
Amortisation	0.0	0.0	0.0	0.0	0.0
EBIT	50.1	18.7	19.5	21.0	22.6
Net interest income /(exp)	(3.0)	(3.9)	(5.5)	(5.4)	(5.3)
Associates & JV	(0.5)	(0.5)	(0.4)	(0.3)	(0.2)
Exceptionals	0.0	0.0	0.0	0.0	0.0
Other pretax income	0.0	0.0	0.0	0.0	0.0
Pretax profit	46.7	14.3	13.6	15.3	17.1
Income tax	(7.3)	(2.4)	(2.2)	(2.5)	(2.7)
Minorities	(8.9)	(0.5)	(0.8)	(0.7)	(0.6)
Discontinued operations	0.0	0.0	0.0	0.0	0.0
Reported net profit	30.5	11.3	10.7	12.2	13.8
Core net profit	26.5	16.2	10.7	12.2	13.8
BALANCE SHEET (SGD m)					
Cash & Short Term Investments	47.6	39.7	41.7	40.3	39.3
Accounts receivable	27.8	27.0	24.5	24.9	25.2
Inventory	15.9	11.1	12.3	13.3	13.5
Reinsurance assets	0.0	0.0	0.0	1.0	2.0
Property, Plant & Equip (net)	84.3	89.5	80.7	71.7	62.5
Intangible assets	60.2	61.2	61.2	61.2	61.2
Investment in Associates & JVs	27.0	25.2	25.2	25.2	25.2
Other assets	13.3	13.8	13.8	14.8	15.8
Total assets	276.2	267.4	259.3	252.4	244.7
ST interest bearing debt	1.9	1.9	1.9	1.9 21.8	1.9
Accounts payable	26.2 0.0	19.4	21.6 0.0		21.9 2.0
Insurance contract liabilities LT interest bearing debt	75.5	0.0 75.5	75.5	1.0 75.5	75.5
Other liabilities	69.0	68.0	68.0	68.0	68.0
Total Liabilities	172.9	165.2	167.4	168.5	169.7
Shareholders Equity	97.8	96.5	91.2	82.2	72.4
Minority Interest	5.4	5.8	0.8	0.7	0.6
Total shareholder equity	103.2	102.2	92.0	82.9	73.0
Perpetual securities	0.0	0.0	0.0	1.0	2.0
Total liabilities and equity	276.2	267.4	259.3	252.4	244.7
CASH FLOW (SGD m)					
Pretax profit	46.7	14.3	13.6	15.3	17.1
Depreciation & amortisation	13.6	17.1	17.8	18.0	18.2
Adj net interest (income)/exp	3.0	3.9	5.5	5.4	5.3
Change in working capital	(5.6)	4.2	1.6	(1.1)	(0.3)
Cash taxes paid	(3.1)	(6.2)	(1.2)	(1.2)	(1.2)
Other operating cash flow	(3.7)	0.4	0.9	0.8	0.7
Cash flow from operations	50.8	33.6	38.3	37.3	39.9
Capex	(8.6)	(10.8)	(9.0)	(9.0)	(9.0)
Free cash flow	42.3	22.8	29.3	28.3	30.9
Dividends paid	(48.8)	(18.2)	(4.7)	(7.1)	(9.5)
Equity raised / (purchased)	(3.1)	0.0	0.0	0.0	0.0
Perpetual securities	0.0	0.0	0.0	1.0	2.0
Change in Debt	8.5	(0.9)	(10.0)	(10.0)	(10.0)
Perpetual securities distribution	0.0	0.0	0.0	1.0	2.0
Other invest/financing cash flow	(17.1)	(11.6)	(12.5)	(9.5)	(6.5)
Effect of exch rate changes Net cash flow	0.0 (18.1)	0.0 (7.9)	0.0 2.0	1.0 4.6	2.0 10.9

FYE 31 Dec	FY21A	FY22A	FY23E	FY24E	FY25E
Key Ratios					
Growth ratios (%)					
Revenue growth	49.4	(11.9)	(3.4)	1.5	1.5
EBITDA growth	69.8	(43.9)	4.4	4.6	4.5
EBIT growth	92.9	(62.7)	4.4	7.8	7.4
Pretax growth	108.5	(69.4)	(4.8)	12.7	11.5
Reported net profit growth	54.7	(62.9)	(5.7)	14.5	12.9
Core net profit growth	34.4	(38.8)	(34.2)	14.5	12.9
Profitability ratios (%)					
EBITDA margin	31.0	19.7	21.3	22.0	22.6
EBIT margin	24.4	10.3	11.1	11.8	12.5
Pretax profit margin	22.7	7.9	7.8	8.6	9.5
Payout ratio	123.9	83.7	44.4	58.1	68.6
DuPont analysis					
Net profit margin (%)	14.8	6.2	6.1	6.9	7.6
Revenue/Assets (x)	0.7	0.7	0.7	0.7	0.7
Assets/Equity (x)	2.8	2.8	2.8	3.1	3.4
ROAE (%)	27.8	11.6	11.4	14.1	17.8
ROAA (%)	9.6	6.0	4.0	4.8	5.5
Liquidity & Efficiency					
Cash conversion cycle	(3.4)	(25.0)	(25.2)	(27.7)	(22.8)
Days receivable outstanding	40.3	54.4	52.9	50.0	50.0
Days inventory outstanding	129.5	115.0	103.6	112.0	116.1
Days payables outstanding	173.2	194.5	181.8	189.8	188.9
Dividend cover (x)	0.8	1.2	2.3	1.7	1.5
Current ratio (x)	2.1	2.5	2.4	2.3	2.3
Leverage & Expense Analysis					
Asset/Liability (x)	1.6	1.6	1.5	1.5	1.4
Net gearing (%) (incl perps)	28.8	36.9	38.8	44.2	50.9
Net gearing (%) (excl. perps)	28.8	36.9	38.8	44.7	52.3
Net interest cover (x)	16.7	4.8	3.5	3.9	4.2
Debt/EBITDA (x)	1.2	2.2	2.1	2.0	1.9
Capex/revenue (%)	4.2	5.9	5.1	5.1	5.0
Net debt/ (net cash)	29.8	37.7	35.7	37.0	38.1

Source: Company; Maybank IBG Research

### **Research Offices**

#### **ECONOMICS**

Suhaimi ILIAS Chief Economist Malaysia | Philippines | Global (603) 2297 8682 suhaimi\_ilias@maybank-ib.com

**CHUA Hak Bin** 

gional Thematic Macroeconomist chuahb@maybank.com

Dr Zamros DZULKAFLI Malaysia | Philippines (603) 2082 6818

zamros.d@maybank-ib.com

Erica TAY China | Thailand (65) 6231 5844 erica.tay@maybank.com

Brian LEE Shun Rong Indonesia | Singapore | Vietnam (65) 6231 5846

Fatin Nabila MOHD ZAINI

(603) 2297 8685 fatinnabila.mohdzaini@maybank-ib.com

Luong Thu Huong (65) 6231 8467 hana.thuhuong@maybank.com

#### FX

Saktiandi SUPAAT Head of FX Research (65) 6320 1379 saktiandi@maybank.com

(65) 6320 1374 fionalim@maybank.com

Alan LAU (65) 6320 1378 alanlau@maybank.com

Shaun LIM (65) 6320 1371 shaunlim@maybank.com

#### STRATEGY

Anand PATHMAKANTHAN

(603) 2297 8783 anand.pathmakanthan@maybank-ib.com

#### FIXED INCOME

Winson PHOON, FCA Head of Fixed Income (65) 6340 1079 winsonphoon@maybank.com

(603) 2074 7606 munyi.st@maybank-ib.com

#### PORTFOLIO STRATEGY

#### MIBG SUSTAINABILITY RESEARCH

Jigar SHAH Head of Sustainability Research (91) 22 4223 2632 jigars@maybank.com

Neerav DALAL (91) 22 4223 2606 neerav@maybank.com

#### **REGIONAL EQUITIES**

Anand PATHMAKANTHAN Head of Regional Equity Research (603) 2297 8783 anand.pathmakanthan@maybank-ib.com

WONG Chew Hann, CA Head of ASEAN Equity Research (603) 2297 8686 wchewh@maybank-ib.com

#### ΜΑΙ ΔΥSΙΔ

Anand PATHMAKANTHAN Head of Research (603) 2297 8783 anand.pathmakanthan@maybank-ib.com

Strategy

WONG Chew Hann, CA (603) 2297 8686 wchewh@mavbank-ib.com

Non-Bank Financials (stock exchange)
Construction & Infrastructure

Desmond CH'NG, BFP, FCA (603) 2297 8680 desmond.chng@maybank-ib.com

Banking & Finance

ONG Chee Ting, CA (603) 2297 8678 ct.ong@maybank-ib.com • Plantations - Regional

YIN Shao Yang, CPA

(603) 2297 8916 samuel.y@maybank-ib.com • Gaming - Regional • Media • Aviation • Non-Bank Financials

TAN Chi Wei, CFA (603) 2297 8690 chiwei.t@maybank-ib.com Power • Telcos

WONG Wei Sum, CFA (603) 2297 8679 weisum@maybank-ib.com • Property • Glove

(603) 2297 8687 jade.tam@maybank-ib.com Consumer Staples & Discretionary

Nur Farah SYIFAA (603) 2297 8675 nurfarahsyifaa.mohamadfuad@maybank-ib.com · Renewable Energy · REITs

LOH Yan Jin (603) 2297 8687 lohyanjin.loh@maybank-ib.com Ports • Shipping • Automotive

Arvind JAYARATNAM (603) 2297 8692 arvind.jayaratnam@maybank.com
• Petrochemicals • Technology

TEE Sze Chiah Head of Retail Research (603) 2082 6858 szechiah.t@maybank-ib.com • Retail Research

Nik Ihsan RAJA ABDULLAH, MSTA, CFTe (603) 2297 8694 nikmohdihsan.ra@maybank-ib.com

Chartist

Amirah ∆7MI

(603) 2082 8769 amirah.azmi@maybank-ib.com
• Retail Research

#### SINGAPORE

Thilan WICKRAMASINGHE Head of Research (65) 6231 5840 thilanw@maybank.com
• Banking & Finance - Regional

• Consumer

Eric ONG (65) 6231 5849 ericong@maybank.com · Healthcare · Transport · SMIDs

(65) 6231 5837 kelvin.tan1@maybank.com • Telcos • Industrials

LI Jialin (65) 6231 5845 jialin.li@maybank.com

• RFITs

Jarick SEET (65) 6231 5848 jarick.seet@maybank.com Technology

Krishna GUHA (65) 6231 5842 krishna.guha@maybank.com • REITs

#### **PHILIPPINES**

Jacqui de JESUS Head of Research (63) 2 8849 8840 jacqui.dejesus@maybank.com
• Strategy • Conglomerates

Rachelleen RODRIGUEZ, CFA (63) 2 8849 8843 rachelleen.rodriguez@maybank.com • Banking & Finance • Transport • Telcos

Danhne S7F (63) 2 8849 8847 daphne.sze@maybank.com Consumer

Fiorenzo de JESUS (63) 2 8849 8846 fiorenzo.dejesus@maybank.com Utilities

Alexa Mae CARVAJAL (63) 2 8849 8838 alexamae.carvajal@maybank.com
• Consumer • Gaming • Property • REITs

#### THAILAND

Chak REUNGSINPINYA Head of Research (66) 2658 5000 ext 1399 chak.reungsinpinya@maybank.com
• Strategy • Energy

Jesada TECHAHUSDIN, CFA (66) 2658 5000 ext 1395 iesada.t@maybank.com Banking & Finance

Wasu MATTANAPOTCHANART (66) 2658 5000 ext 1392 vasu.m@maybank.com Telcos • REITs

Surachai PRAMUALCHAROENKIT (66) 2658 5000 ext 1470 Surachai.p@maybank.com • Auto • Conmat • Contractor • Steel

Suttatip PEERASUB (66) 2658 5000 ext 1430 suttatip.p@maybank.com • Food & Beverage • Commerce

#### INDONESIA

Jeffrosenberg CHENLIM Head of Research (62) 21 8066 8680 Jeffrosenberg.lim@maybank.com • Strategy • Banking & Finance • Property

Willy GOUTAMA (62) 21 8066 8500 willy.goutama@maybank.com • Consumer

Etta Rusdiana PUTRA (62) 21 8066 8683 etta.putra@maybank.com
• Telcos

William Jefferson W (62) 21 8066 8563 william.jefferson@maybank.com Property

Adi WICAKSONO (62) 21 8066 8686 Adi.Wicaksono@mavbank.com Plantations

Satriawan HARYONO, CEWA, CTA (62) 21 8066 8682 satriawan@maybank.com Chartist

VIETNAM

Quan Trong Thanh Head of Research (84 28) 44 555 888 ext 8184 thanh.quan@maybank.com • Strategy • Banks

Hoang Huy, CFA (84 28) 44 555 888 ext 8181 hoanghuy@maybank.com Strategy • Technology

Le Nguyen Nhat Chuyen (84 28) 44 555 888 ext 8082 chuyen.le@maybank.com
• Oil & Gas • Logistics

Nguyen Thi Sony Tra Mi (84 28) 44 555 888 ext 8084 trami.nguyen@maybank.com
Consumer Discretionary

Tran Thi Thanh Nhan (84 28) 44 555 888 ext 8088 nhan.tran@maybank.com Consumer Staples

Nguyen Le Tuan Loi (84 28) 44 555 888 ext 8182 loi.nguyen@maybank.com Industrials

Nguyen Thi Ngan Tuyen Head of Retail Research (84 28) 44 555 888 ext 8081 tuyen.nguyen@maybank.com
• Retail Research

Nguven Thanh Lam (84 28) 44 555 888 ext 8086 thanhlam.nguyen@maybank.com Chartist

#### APPENDIX I: TERMS FOR PROVISION OF REPORT, DISCLAIMERS AND DISCLOSURES

#### **DISCLAIMERS**

This research report is prepared for general circulation and for information purposes only and under no circumstances should it be considered or intended as an offer to sell or a solicitation of an offer to buy the securities referred to herein. Investors should note that values of such securities, if any, may fluctuate and that each security's price or value may rise or fall. Opinions or recommendations contained herein are in form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from the relevant jurisdiction's stock exchange in the equity analysis. Accordingly, investors' returns may be less than the original sum invested. Past performance is not necessarily a guide to future performance. This report is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this report. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

The information contained herein has been obtained from sources believed to be reliable but such sources have not been independently verified by Maybank Investment Bank Berhad, its subsidiary and affiliates (collectively, "Maybank IBG") and consequently no representation is made as to the accuracy or completeness of this report by Maybank IBG and it should not be relied upon as such. Accordingly, Maybank IBG and its officers, directors, associates, connected parties and/or employees (collectively, "Representatives") shall not be liable for any direct, indirect or consequential losses or damages that may arise from the use or reliance of this report. Any information, opinions or recommendations contained herein are subject to change at any time, without prior notice.

This report may contain forward looking statements which are often but not always identified by the use of words such as "anticipate", "estimate", "intend", "plan", "expect", "forecast", "predict" and "project" and statements that an event or result "may", "will", "can", "should", "could" or "might" occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward looking statements. Readers are cautioned not to place undue relevance on these forward-looking statements. Maybank IBG expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

Maybank IBG and its officers, directors and employees, including persons involved in the preparation or issuance of this report, may, to the extent permitted by law, from time to time participate or invest in financing transactions with the issuer(s) of the securities mentioned in this report, perform services for or solicit business from such issuers, and/or have a position or holding, or other material interest, or effect transactions, in such securities or options thereon, or other investments related thereto. In addition, it may make markets in the securities mentioned in the material presented in this report. One or more directors, officers and/or employees of Maybank IBG may be a director of the issuers of the securities mentioned in this report to the extent permitted by law.

This report is prepared for the use of Maybank IBG's clients and may not be reproduced, altered in any way, transmitted to, copied or distributed to any other party in whole or in part in any form or manner without the prior express written consent of Maybank IBG and Maybank IBG and its Representatives accepts no liability whatsoever for the actions of third parties in this respect.

This report is not directed to or intended for distribution to or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. This report is for distribution only under such circumstances as may be permitted by applicable law. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Without prejudice to the foregoing, the reader is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

#### Malaysia

Opinions or recommendations contained herein are in the form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from Bursa Malaysia Securities Berhad in the equity analysis.

#### Singapore

This report has been produced as of the date hereof and the information herein may be subject to change. Maybank Research Pte. Ltd. ("MRPL") in Singapore has no obligation to update such information for any recipient. For distribution in Singapore, recipients of this report are to contact MRPL in Singapore in respect of any matters arising from, or in connection with, this report. If the recipient of this report is not an accredited investor, expert investor or institutional investor (as defined under Section 4A of the Singapore Securities and Futures Act), MRPL shall be legally liable for the contents of this report, with such liability being limited to the extent (if any) as permitted by law.

### Thailand

Except as specifically permitted, no part of this presentation may be reproduced or distributed in any manner without the prior written permission of Maybank Securities (Thailand) Public Company Limited. Maybank Securities (Thailand) Public Company Limited ("MST") accepts no liability whatsoever for the actions of third parties in this respect.

Due to different characteristics, objectives and strategies of institutional and retail investors, the research products of MST Institutional and Retail Research departments may differ in either recommendation or target price, or both. MST reserves the rights to disseminate MST Retail Research reports to institutional investors who have requested to receive it. If you are an authorised recipient, you hereby tacitly acknowledge that the research reports from MST Retail Research are first produced in Thai and there is a time lag in the release of the translated English version.

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey may be changed after that date. MST does not confirm nor certify the accuracy of such survey result.

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, MST does not confirm, verify, or certify the accuracy and completeness of the assessment result.

#### US

This third-party research report is distributed in the United States ("US") to Major US Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended) only by Wedbush Securities Inc. ("Wedbush"), a broker-dealer registered in the US (registered under Section 15 of the Securities Exchange Act of 1934, as amended). All responsibility for the distribution of this report by Wedbush in the US shall be borne by Wedbush. This report is not directed at you if Wedbush is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. You should satisfy yourself before reading it that Wedbush is permitted to provide research material concerning investments to you under relevant legislation and regulations. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security mentioned within must do so with: Wedbush Securities Inc. 1000 Wilshire Blvd, Los Angeles, California 90017, +1 (646) 604-4232 and not with the issuer of this report.



#### UK

This document is being distributed by Maybank Securities (London) Ltd ("MSUK") which is authorized and regulated, by the Financial Conduct Authority and is for Informational Purposes only. This document is not intended for distribution to anyone defined as a Retail Client under the Financial Services and Markets Act 2000 within the UK. Any inclusion of a third party link is for the recipients convenience only, and that the firm does not take any responsibility for its comments or accuracy, and that access to such links is at the individuals own risk. Nothing in this report should be considered as constituting legal, accounting or tax advice, and that for accurate guidance recipients should consult with their own independent tax advisers.

#### **DISCLOSURES**

#### **Legal Entities Disclosures**

Malaysia: This report is issued and distributed in Malaysia by Maybank Investment Bank Berhad (15938- H) which is a Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets and Services License issued by the Securities Commission in Malaysia. Singapore: This report is distributed in Singapore by MRPL (Co. Reg No 198700034E) which is regulated by the Monetary Authority of Singapore. Indonesia: PT Maybank Sekuritas Indonesia ("PTMSI") (Reg. No. KEP-251/PM/1992) is a member of the Indonesia Stock Exchange and is regulated by the Financial Services Authority (Indonesia). Thailand: MST (Reg. No.0107545000314) is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission. Philippines: Maybank Securities Inc (Reg. No.01-2004-00019) is a member of the Philippines Stock Exchange and is regulated by the Securities and Exchange Commission. Vietnam: Maybank Securities Limited (License Number: 117/GP-UBCK) is licensed under the State Securities Commission of Vietnam. Hong Kong: MIB Securities (Hong Kong) Limited (Central Entity No AAD284) is regulated by the Securities and Futures Commission. India: MIB Securities India Private Limited ("MIBSI") is a participant of the National Stock Exchange of India Limited and the Bombay Stock Exchange and is regulated by Securities and Exchange Board of India ("SEBI") (Reg. No. INZ000010538). MIBSI is also registered with SEBI as Category 1 Merchant Banker (Reg. No. INM 000011708) and as Research Analyst (Reg No: INH000000057). UK: Maybank Securities (London) Ltd (Reg No 2377538) is authorized and regulated by the Financial Conduct Authority.

#### **Disclosure of Interest**

Malaysia: Maybank IBG and its Representatives may from time to time have positions or be materially interested in the securities referred to herein and may further act as market maker or may have assumed an underwriting commitment or deal with such securities and may also perform or seek to perform investment banking services, advisory and other services for or relating to those companies.

Singapore: As of 23 August 2023, Maybank Research Pte. Ltd. and the covering analyst do not have any interest in any companies recommended in this research report.

**Thailand:** MST may have a business relationship with or may possibly be an issuer of derivative warrants on the securities /companies mentioned in the research report. Therefore, Investors should exercise their own judgment before making any investment decisions. MST, its associates, directors, connected parties and/or employees may from time to time have interests and/or underwriting commitments in the securities mentioned in this report.

Hong Kong: As of 23 August 2023, MIB Securities (Hong Kong) Limited and the authoring analyst do not have any interest in any companies recommended in this research report.

India: As of 23 August 2023, and at the end of the month immediately preceding the date of publication of the research report, MIBSI, authoring analyst or their associate / relative does not hold any financial interest or any actual or beneficial ownership in any shares or having any conflict of interest in the subject companies except as otherwise disclosed in the research report. In the past twelve months MIBSI and authoring analyst or their associate did not receive any compensation or other benefits from the subject companies or third party in connection with the research report on any account what so ever except as otherwise disclosed in the research report.

Maybank IBG may have, within the last three years, served as manager or co-manager of a public offering of securities for, or currently may make a primary market in issues of, any or all of the entities mentioned in this report or may be providing, or have provided within the previous 12 months, significant advice or investment services in relation to the investment concerned or a related investment and may receive compensation for the services provided from the companies covered in this report.

#### **OTHERS**

#### **Analyst Certification of Independence**


The views expressed in this research report accurately reflect the analyst's personal views about any and all of the subject securities or issuers; and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.

#### Reminder

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct its own analysis of the product and consult with its own professional advisers as to the risks involved in making such a purchase.

No part of this material may be copied, photocopied or duplicated in any form by any means or redistributed without the prior consent of Maybank IBG.

#### Historical recommendations and target price: Q&M Dental Group (QNM SP)



#### **Definition of Ratings**

Maybank IBG Research uses the following rating system

BUY Return is expected to be above 10% in the next 12 months (including dividends)

HOLD Return is expected to be between 0% to 10% in the next 12 months (including dividends)

SELL Return is expected to be below 0% in the next 12 months (including dividends)

#### Applicability of Ratings

The respective analyst maintains a coverage universe of stocks, the list of which may be adjusted according to needs. Investment ratings are only applicable to the stocks which form part of the coverage universe. Reports on companies which are not part of the coverage do not carry investment ratings as we do not actively follow developments in these companies.



### Malaysia

Maybank Investment Bank Berhad (A Participating Organisation of Bursa Malaysia Securities Berhad) 33rd Floor, Menara Maybank, 100 Jalan Tun Perak, 50050 Kuala Lumpur

Tel: (603) 2059 1888; Fax: (603) 2078 4194

Stockbroking Business:

Level 8, Tower C, Dataran Maybank, No.1, Jalan Maarof 59000 Kuala Lumpur

Tel: (603) 2297 8888 Fax: (603) 2282 5136

Sales Trading

Indonesia

Helen Widjaja

Philippines Keith Roy

helen.widjaja@maybank.com (62) 21 2557 1188

keith\_roy@maybank.com Tel: (63) 2 848-5288

### Singapore

Maybank Securities Pte Ltd Maybank Research Pte Ltd 50 North Canal Road Singapore 059304

Tel: (65) 6336 9090

### Indonesia

PT Maybank Sekuritas Indonesia Sentral Senayan III, 22nd Floor Jl. Asia Afrika No. 8 Gelora Bung Karno, Senayan Jakarta 10270, Indonesia

Tel: (62) 21 2557 1188 Fax: (62) 21 2557 1189

#### Thailand

Maybank Securities (Thailand) PCL 999/9 The Offices at Central World, 20th - 21st Floor, Rama 1 Road Pathumwan.

Tel: (66) 2 658 6817 (sales)

Bangkok 10330, Thailand

### Tel: (66) 2 658 6801 (research)

#### London

**Greg Smith** gsmith@maybank.com Tel: (44) 207-332-0221

Sanjay Makhija sanjaymakhija@maybank.com Tel: (91)-22-6623-2629

### London

Maybank Securities (London) Ltd PNB House 77 Queen Victoria Street London EC4V 4AY, UK

Tel: (44) 20 7332 0221 Fax: (44) 20 7332 0302

### India

MIB Securities India Pte Ltd 1101, 11th floor, A Wing, Kanakia Wall Street, Chakala, Andheri -Kurla Road, Andheri East, Mumbai City - 400 093, India

Tel: (91) 22 6623 2600 Fax: (91) 22 6623 2604

### Vietnam

Maybank Securities Limited Floor 10, Pearl 5 Tower, 5 Le Quy Don Street, Vo Thi Sau Ward, District 3 Ho Chi Minh City, Vietnam

Tel: (84) 28 44 555 888 Fax: (84) 28 38 271 030

### Hong Kong

MIB Securities (Hong Kong) Limited 28/F, Lee Garden Three, 1 Sunning Road, Causeway Bay, Hong Kong

Tel: (852) 2268 0800 Fax: (852) 2877 0104

### Philippines

Maybank Securities Inc 17/F, Tower One & Exchange Plaza Ayala Triangle, Ayala Avenue Makati City, Philippines 1200

Tel: (63) 2 8849 8888 Fax: (63) 2 8848 5738

www.maybank.com/investment-banking www.maybank-keresearch.com